Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00664807 · ClinicalTrials.gov registry record
Medtronic Genetic Arrhythmia Markers for Early Detection (GAME Study)
A clinical trial, sponsored by Medtronic Corporate Technologies and New Ventures.
- Completed
- Registry status
- 1,023
- Enrollment target
NCT00664807: Completed study, sponsored by Medtronic Corporate Technologies and New Ventures.
NCT00664807 is a clinical trial that has completed, run by Medtronic Corporate Technologies and New Ventures. The registered enrollment target is 1,023 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00664807 has completed, sponsored by Medtronic Corporate Technologies and New Ventures.
- COMPLETED
- Registry status
- 1,023 participants
- Enrollment target
Study Summary
To generate a list of potential genetic markers that correlate with an increased risk of life-threatening arrhythmias. To evaluate ECG-based risk markers such as heart rate variability and T-wave Alternans for their association with arrhythmic events.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,023 participants |
| Start Date | 2008-04 |
| Est. Completion | 2009-05 |
What the finished NCT00664807 record still lists
NCT00664807 is an observational study that tracks outcomes without assigning an intervention. Its 1,023 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT00664807 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00664807 about?
NCT00664807 is a clinical study titled "Medtronic Genetic Arrhythmia Markers for Early Detection (GAME Study)". To generate a list of potential genetic markers that correlate with an increased risk of life-threatening arrhythmias. To evaluate ECG-based risk markers such as heart rate variability and T-wave Alternans for their association with arrhythmic events.
What is the current status of trial NCT00664807?
This trial is currently completed. The enrollment target is 1,023 participants. The study started on 2008-04. Estimated completion is 2009-05.
Who is sponsoring clinical trial NCT00664807?
This trial is sponsored by Medtronic Corporate Technologies and New Ventures, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07216703 · 1,023 participants · Phase 3
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
- NCT06888011 · 1,024 participants · NA
iAmHealthy Clinical Practice Guideline (CPG)
- NCT02200276 · 1,025 participants · NA
Influenza Immunization in Adults Over Age 75
- NCT02296450 · 1,025 participants
Quality of Life (QoL) Assessment in Cancer Patients and Survivors With Dermatologic Conditions Using Dermatologic QoL Instruments
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia